Synonyms: Masivet, Kinavet, AB1010, Masitinib mesylate
Therapy Type: Small Molecule (timeline)
Target Type: Other (timeline)
Condition(s): Alzheimer's Disease, Amyotrophic Lateral Sclerosis
U.S. FDA Status: Alzheimer's Disease (Phase 3), Amyotrophic Lateral Sclerosis (Phase 3)
Company: AB Science
Masitinib is an orally available inhibitor of the protein tyrosine kinase c-kit, which is expressed on cancer cells. Masitinib also inhibits PDGF and FGF receptors, and fyn and lyn kinases (Dubreuil et al., 2009). Masitinib interferes with the survival, migration, and activity of mast cells, and in this role has attracted attention for the treatment of neuroinflammatory and neurodegenerative disorders. Also relevant to Alzheimer’s, AB Science claims masitinib modulates microglia through inhibition of the macrophage colony stimulating factor receptor 1 kinase.
In preclinical work, chronic treatment with masitinib was reported to restore spatial learning and synaptic density in the hippocampus in the APP/PS1 mouse model of amyloidosis (Li et al., 2020).
From 2006 to 2009, AB Science conducted a Phase 2 trial comparing 3 and 6 mg/kg/day of masitinib or placebo, taken twice daily for six months as an add-on therapy to cholinesterase inhibitor and/or memantine treatment. Conducted at 12 centers in France, this trial enrolled 34 patients with mild to moderate Alzheimer's disease and used change in cognition as measured by the ADAS-Cog as primary outcome. Masitinib was reported to have reduced cognitive decline in this study, with a claimed effect size of 6.8 and 7.6 at three and six months, respectively. Side effects including gastrointestinal disorders, edema, and rash occurred about twice as often with masitinib than placebo. Nineteen of 34 participants in the masitinib group withdrew before the study completed, compared with two of the eight placebo participants. Seven of the 19 withdrawals were reported as due to treatment-related adverse effects. The drug's tolerance was called acceptable in this report (Piette et al., 2011).
In 2012, a Phase 2b/3 trial began. Conducted in six European countries, it was to enroll 396 patients with mild to moderate Alzheimer's, comparing six months of 3 or 4.5 mg/kg daily, or placebo, as an add-on to cholinesterase and memantine treatment. In 2018, the study was enlarged to enroll 721 people from 118 sites in 21 mainly European countries, and added a dose escalation group receiving 4.5 mg/kg daily for three months, then 6 mg/kg, with a matching placebo group. The 3. 5 mg/kg group was discontinued. Cognition as measured by ADAS-cog and global function as measured by the ADCS-ADL were co-primary outcome measures.
In late 2020, the company announced that the study met its primary goal (Dec 2020 news). The 4.5 mg/kg treatment group improved on ADAS-cog and ADCS-ADL, while the placebo group declined. The ADAS-Cog met the preset statistical threshold for success of p<0.025. Fewer drug- than placebo-treated participants progressed to severe dementia. No treatment effect was seen in the titration arm. Serious adverse events were twice as frequent in treated groups than placebo.
In addition, masitinib was evaluated in Spain for amyotrophic lateral sclerosis as an add-on therapy to riluzole. This trial started in January 2013 as a Phase 2 with 45 patients but later was expanded into a Phase 3 study with 349 patients (see clinicaltrials.gov). The company reported positive results for this study (May 2017 news), and subsequently published the data in a peer reviewed (Mora et al., 2019). In October 2020, a confirmatory Phase 3 study began evaluating 48 weeks of 4.5 and 6 mg/kg or placebo in 495 participants. It will run through 2022.
AB Science is also developing masitinib for multiple sclerosis, where it was reported to slow disease progression in a Phase 3 trial (2020 abstract). Clinical development for pancreatic cancer, asthma, mastocytosis, and COVID-19 disease is ongoing, as well. Masitinib has been tested in clinical trials for breast, colorectal, gastric, head and neck, liver, lung, and oesophageal cancer, as well as glioblastoma, metastatic melanoma, multiple myeloma, and T cell lymphoma. The drug is available to treat cancer in veterinary medicine under the names Masivet or Kinavet.
For all trials of masitinib in Alzheimer's, see clinicaltrials.gov.
Clinical Trial Timeline
- Phase 2
- Phase 3
- Study completed / Planned end date
- Planned end date unavailable
- Study aborted
Last Updated: 08 Jan 2021
- Positive Phase 2 Results Claimed for Masitinib in Alzheimer’s
- Certain Cancer Drugs Held Out as Prospects for ALS Therapy
- Piette F, Belmin J, Vincent H, Schmidt N, Pariel S, Verny M, Marquis C, Mely J, Hugonot-Diener L, Kinet JP, Dubreuil P, Moussy A, Hermine O. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther. 2011 Apr 19;3(2):16. PubMed.
- Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hernández M, Marín S, Mascias J, Rodriguez GE, Povedano M, Paipa A, Dominguez R, Gamez J, Salvado M, Lunetta C, Ballario C, Riva N, Mandrioli J, Moussy A, Kinet JP, Auclair C, Dubreuil P, Arnold V, Mansfield CD, Hermine O, AB10015 STUDY GROUP. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2019 Jul 7;:1-10. PubMed.
- Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Castéran N, Borge L, Hajem B, Lermet A, Sippl W, Voisset E, Arock M, Auclair C, Leventhal PS, Mansfield CD, Moussy A, Hermine O. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One. 2009 Sep 30;4(9):e7258. PubMed.
- Li T, Martin E, Abada YS, Boucher C, Cès A, Youssef I, Fenaux G, Forand Y, Legrand A, Nachiket N, Dhenain M, Hermine O, Dubreuil P, Delarasse C, Delatour B. Effects of Chronic Masitinib Treatment in APPswe/PSEN1dE9 Transgenic Mice Modeling Alzheimer's Disease. J Alzheimers Dis. 2020;76(4):1339-1345. PubMed.
No Available Further Reading